Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru


ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Лечебное дело
2021 / N 4

Сердечная недостаточность с сохраненной фракцией выброса левого желудочка: возможности диагностики и стратификации риска у пожилых пациентов
В.Н. Ларина, В.И. Лунев, Д.Г. Карпенко, В.П. Сидорова

Список литературы

1. Powell-Wiley TM, Ngwa J, Kebede S, Lu D, Schulte PJ, Bhatt DL, Yancy C, Fonarow GC, Albert MA. Impact of body mass index on heart failure by race/ethnicity from the get with the guidelines-heart failure (GWTG-HF) registry. JACC. Heart Failure 2018 Mar;6(3):233-42.
2. Crespo-Leiro MG, Anker SD, Maggioni AP, Coats AJ, Filippatos G, Ruschitzka F, Ferrari R, Piepoli MF, Delgado Jimenez JF, Metra M, Fonseca C, Hradec J, Amir O, Logeart D, Dahlström U, Merkely B, Drozdz J, Goncalvesova E, Hassanein M, Chioncel O, Lainscak M, Seferovic PM, Tousoulis D, Kavoliuniene A, Fruhwald F, Fazlibegovic E, Temizhan A, Gatzov P, Erglis A, Laroche C, Mebazaa A; Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Society of Cardiology Heart Failure Long-Term registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. European Journal of Heart Failure 2016 Jun;18(6):613-25.
3. Терещенко С.Н., Галявич А.С., Ускач Т.М., Агеев Ф.Т., Арутюнов Г.П., Беграмбекова Ю.Л., Беленков Ю.Н., Бойцов С.А., Васюк Ю.А., Гарганеева А.А., Гендлин Г.Е., Гиляревский С.Р., Глезер М.Г., Готье С.В., Гупало Е.М., Довженко Т.В., Драпкина О.М., Дупляков Д.В., Жиров И.В., Затейщиков Д.А., Кобалава Ж.Д., Козиолова Н.А., Коротеев А.В., Либис Р.А., Лопатин Ю.М., Мареев В.Ю., Мареев Ю.В., Мацкеплишвили С.Т., Насонова С.Н., Нарусов О.Ю., Недошивин А.О., Овчинников А.Г., Орлова Я.А., Перепеч Н.Б., Самко А.Н., Саидова М.А., Сафиуллина А.А., Ситникова М.Ю., Скворцов А.А., Скибицкий В.В., Стукалова О.В., Тарловская Е.И., Терещенко А.С., Чесникова А.И., Фомин И.В., Шевченко А.О., Шапошник И.И., Шария М.А., Шляхто Е.В., Явелов И.С., Якушин С.С. Хроническая сердечная недостаточность. Клинические рекомендации 2020. Российский кардиологический журнал 2020;25(11):311-74.
4. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Piepoli MF, Price S, Rosano GMC, Ruschitzka F, Skibelund AK; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal 2021 Sep;42(36):3599-726.
5. Bozkurt B, Coats AJ, Tsutsui H, Abdelhamid M, Adamopoulos S, Albert N, Anker SD, Atherton J, Böhm M, Butler J, Drazner MH, Felker GM, Filippatos G, Fonarow GC, Fiuzat M, Gomez-Mesa JE, Heidenreich P, Imamura T, Januzzi J, Jankowska EA, Khazanie P, Kinugawa K, Lam CSP, Matsue Y, Metra M, Ohtani T, Francesco Piepoli M, Ponikowski P, Rosano GMC, Sakata Y, Seferović P, Starling RC, Teerlink JR, Vardeny O, Yamamoto K, Yancy C, Zhang J, Zieroth S. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. Journal of Cardiac Failure 2021 Apr;27(4):387-413.
6. Levinson RT, Vaitinidin NS, Farber-Eger E, Roden DM, Lasko TA, Wells QS, Mosley JD. Heart failure clinical care analysis uncovers risk reduction opportunities for preserved ejection fraction subtype. Scientific Reports 2021 Sep;11(1):18618.
7. Cho DH, Yoo BS. Current prevalence, incidence, and outcomes of heart failure with preserved ejection fraction. Heart Failure Clinics 2021 Jul;17(3):315-26.
8. van Riet EE, Hoes AW, Wagenaar KP, Limburg A, Landman MA, Rutten FH. Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review. European Journal of Heart Failure 2016 Mar;18(3):242-52.
9. Фомин И.В. Хроническая сердечная недостаточность в Российской Федерации: что сегодня мы знаем и что должны делать. Российский кардиологический журнал 2016;21(8):7-13.
10. Ощепкова Е.В., Лазарева Н.В., Сатлыкова Д.Ф., Терещенко С.Н. Первые результаты Российского регистра хронической сердечной недостаточности. Кардиология 2015;55(5):22-8.
11. Brouwers FP, de Boer RA, van der Harst P, Voors AA, Gansevoort RT, Bakker SJ, Hillege HL, van Veldhuisen DJ, van Gilst WH. Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. European Heart Journal 2013 May;34(19):1424-31.
12. Silverman MG, Patel B, Blankstein R, Lima JA, Blumenthal RS, Nasir K, Blaha MJ. Impact of race, ethnicity, and multimodality biomarkers on the incidence of new-onset heart failure with preserved ejection fraction (from the multi-ethnic study of atherosclerosis). The American Journal of Cardiology 2016 May;117(9):1474-81.
13. Ho JE, Lyass A, Lee DS, Vasan RS, Kannel WB, Larson MG, Levy D. Predictors of new-onset heart failure: differences in preserved versus reduced ejection fraction. Circulation. Heart Failure 2013 Mar;6(2):279-86.
14. Gerber Y, Weston SA, Redfield MM, Chamberlain AM, Manemann SM, Jiang R, Killian JM, Roger VL. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA. Internal Medicine 2015 Jun;175(6):996-1004.
15. Tsao CW, Lyass A, Enserro D, Larson MG, Ho JE, Kizer JR, Gottdiener JS, Psaty BM, Vasan RS. Temporal trends in the incidence of and mortality associated with heart failure with preserved and reduced ejection fraction. JACC. Heart Failure 2018 Aug;6(8):678-85.
16. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. The Lancet 2003 Sep;362(9386):777-81.
17. Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, van Veldhuisen DJ, Zannad F, Zile MR, Desai AS, Claggett B, Jhund PS, Boytsov SA, Comin-Colet J, Cleland J, Düngen HD, Goncalvesova E, Katova T, Kerr Saraiva JF, Lelonek M, Merkely B, Senni M, Shah SJ, Zhou J, Rizkala AR, Gong J, Shi VC, Lefkowitz MP; PARAGON-HF Investigators and Committees. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. The New England Journal of Medicine 2019 Oct;381(17):1609-20.
18. Драпкина О.М., Бойцов С.А., Омельяновский В.В., Концевая А.В., Лукьянов М.М., Игнатьева В.И., Деркач Е.В. Социально-экономический ущерб, обусловленный хронической сердечной недостаточностью, в Российской Федерации. Российский кардиологический журнал 2021;26(6):81-9.
19. Di Palo KE, Barone NJ. Hypertension and heart failure: prevention, targets, and treatment. Heart Failure Clinics 2020 Jan;16(1):99-106.
20. Hicklin HE, Gilbert ON, Ye F, Brooks JE, Upadhya B. Hypertension as a road to treatment of heart failure with preserved ejection fraction. Current Hypertension Reports 2020 Sep;22(10):82.
21. Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiade M, Greenberg BH, O’Connor CM, Sun JL, Yancy CW, Young JB; OPTIMIZE-HF Investigators and Hospitals. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. Journal of the American College of Cardiology 2007 Aug;50(8):768-77.
22. Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction. Nature Reviews. Cardiology 2017 Oct;14(10):591-602.
23. Мареев В.Ю., Фомин И.В., Агеев Ф.Т., Беграмбекова Ю.Л., Васюк Ю.А., Гарганеева А.А., Гендлин Г.Е., Глезер М.Г., Готье С.В., Довженко Т.В., Кобалава Ж.Д., Козиолова Н.А., Коротеев А.В., Мареев Ю.В., Овчинников А.Г., Перепеч Н.Б., Тарловская Е.И., Чесникова А.И., Шевченко А.О., Арутюнов Г.П., Беленков Ю.Н., Галявич А.С., Гиляревский С..Р, Драпкина О.М., Дубляков Д.В., Лопатин Ю.М., Ситникова М.Ю., Скибицкий В.В., Шляхто Е.В. Клинические рекомендации ОССН-РКО-РНМОТ. Сердечная недостаточность: хроническая (ХСН) и острая декомпенсированная (ОДСН). Диагностика, профилактика и лечение. Кардиология 2018;58(6S):8-158.
24. Васюк Ю.А., Шупенина Е.Ю., Намазова Г.А., Дубровская Т.И. Новые алгоритмы диагностики сердечной недостаточности с сохраненной фракцией выброса левого желудочка у пациентов с артериальной гипертензией и ожирением. Кардиоваскулярная терапия и профилактика 2021;20(1):65-70.
25. Pieske B, Tschöpe C, de Boer RA, Fraser AG, Anker SD, Donal E, Edelmann F, Fu M, Guazzi M, Lam CSP, Lancellotti P, Melenovsky V, Morris DA, Nagel E, Pieske-Kraigher E, Ponikowski P, Solomon SD, Vasan RS, Rutten FH, Voors AA, Ruschitzka F, Paulus WJ, Seferovic P, Filippatos G. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Heart Journal 2019 Oct;40(40):3297-317.
26. Reddy YNV, Carter RE, Obokata M, Redfield MM, Borlaug BA. A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. Circulation 2018 Aug;138(9):861-70.
27. Ларина В.Н., Лунев В.И. Значение биомаркеров в диагностике и прогнозировании сердечной недостаточности в старшем возрасте. Архивъ внутренней медицины 2021;11(2):98-110.
28. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P; Authors/Task Force Members; Document Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Journal of Heart Failure 2016 Aug;18(8):891-975.
29. Salzano A, D’Assante R, Israr MZ, Eltayeb M, D’Agostino A, Bernieh D, De Luca M, Rega S, Ranieri B, Mauro C, Bossone E, Squire IB, Suzuki T, Marra AM. Biomarkers in heart failure: clinical insights. Heart Failure Clinics 2021 Apr;17(2):223-43.
30. Seferović PM, Jankowska E, Coats AJS, Maggioni AP, Lopatin Y, Milinković I, Polovina M, Lainščak M, Timmis A, Huculeci R, Vardas P; Task Force of the HFA Atlas, and the ESC Atlas of Cardiology leadership, developed in collaboration with the National Heart Failure Societies of the ESC member and ESC affiliated member countries. The Heart Failure Association Atlas: rationale, objectives, and methods. European Journal of Heart Failure 2020 Apr;22(4):638-45.
31. Dokainish H, Teo K, Zhu J, Roy A, AlHabib KF, ElSayed A, Palileo-Villaneuva L, Lopez-Jaramillo P, Karaye K, Yusoff K, Orlandini A, Sliwa K, Mondo C, Lanas F, Prabhakaran D, Badr A, Elmaghawry M, Damasceno A, Tibazarwa K, Belley-Cote E, Balasubramanian K, Islam S, Yacoub MH, Huffman MD, Harkness K, Grinvalds A, McKelvie R, Bangdiwala SI, Yusuf S; INTER-CHF Investigators. Global mortality variations in patients with heart failure: results from the International Congestive Heart Failure (INTER-CHF) prospective cohort study. The Lancet. Global Health 2017 Jul;5(7):e665-72.
32. Hessel FP. Overview of the socio-economic consequences of heart failure. Cardiovascular Diagnosis and Therapy 2021 Feb;11(1):254-62.
33. Ibrahim NE, Burnett JC Jr, Butler J, Camacho A, Felker GM, Fiuzat M, O’Connor C, Solomon SD, Vaduganathan M, Zile MR, Januzzi JL Jr. Natriuretic peptides as inclusion criteria in clinical trials: a JACC: Heart Failure Position Paper. JACC: Heart Failure 2020 May;8(5):347-58.
34. Berezin AE, Berezin AA. Biomarker-based guideline-directed medical therapy of heart failure: the gap between guidelines and clinical practice. EMJ Cardiology 2021 Oct;9(1):51-60.
35. Song Y, Li F, Xu Y, Liu Y, Wang Y, Han X, Fan Y, Cao J, Luo J, Sun A, Hu K, Zhou J, Ge J. Prognostic value of sST2 in patients with heart failure with reduced, mid-range and preserved ejection fraction. International Journal of Cardiology 2020 Apr;304:95-100.
36. Watson CJ, Gallagher J, Wilkinson M, Russell-Hallinan A, Tea I, James S, O’Reilly J, O’Connell E, Zhou S, Ledwidge M, McDonald K. Biomarker profiling for risk of future heart failure (HFpEF) development. Journal of Translational Medicine 2021 Feb;19(1):61.
37. Castiglione V, Aimo A, Vergaro G, Saccaro L, Passino C, Emdin M. Biomarkers for the diagnosis and management of heart failure. Heart Failure Reviews 2021 Apr 14. doi: 10.1007/s10741-021-10105-w. Online ahead of print.
38. Yamamoto M, Seo Y, Ishizua T, Nakagawa D, Sato K, Machino-Ohtsuka T, Nishi I, Hamada-Harimura Y, Sai S, Sugano A, Baba M, Higuchi H, Aonuma K, Ohte N, Ieda M. Comparison of soluble ST2, pentraxin-3, galectin-3, and high-sensitivity troponin T of cardiovascular outcomes in patients with acute decompensated heart failure. Journal of Cardiac Failure 2021 Nov;27(11):1240-50.
39. Trippel TD, Mende M, Düngen HD, Hashemi D, Petutschnigg J, Nolte K, Herrmann-Lingen C, Binder L, Hasenfuss G, Pieske B, Wachter R, Edelmann F. The diagnostic and prognostic value of galectin-3 in patients at risk for heart failure with preserved ejection fraction: results from the DIAST-CHF study. ESC Heart Failure 2021 Apr;8(2):829-41.
40. Badrov MB, Mak S, Floras JS. Cardiovascular autonomic disturbances in heart failure with preserved ejection fraction. The Canadian Journal of Cardiology 2021 Apr;37(4):609-20.
41. Vergaro G, Aimo A, Prontera C, Ghionzoli N, Arzilli C, Zyw L, Taddei C, Gabutti A, Poletti R, Giannoni A, Mammini C, Spini V, Passino C, Emdin M. Sympathetic and renin-angiotensin-aldosterone system activation in heart failure with preserved, mid-range and reduced ejection fraction. International Journal of Cardiology 2019 Dec;296:91-7.
42. Jimenez-Marrero S, Moliner P, Rodríguez-Costoya I, Enjuanes C, Alcoberro L, Yun S, Gonzalez-Costello J, Garay A, Tajes M, Calero E, Hidalgo E, Guerrero C, García-Romero E, Díez-López C, Cainzos-Achirica M, Comin-Colet J. Sympathetic activation and outcomes in chronic heart failure: does the neurohormonal hypothesis apply to mid-range and preserved ejection fraction patients? European Journal of Internal Medicine 2020 Nov;81:60-6.
43. Borovac JA, D’Amario D, Bozic J, Glavas D. Sympathetic nervous system activation and heart failure: current state of evidence and the pathophysiology in the light of novel biomarkers. World Journal of Cardiology 2020 Aug;12(8):373-408.
44. Чазова И.Е., Мартынюк Т.В., Валиева З.С., Азизов В.А., Акчурин Р.С., Аншелес А.А., Васильцева О.Я., Веселова Т.Н., Галявич А.С., Горбачевский С.В., Данилов Н.М., Едемский А.Г., Зелвеян П.А., Лазарева И.В., Матчин Ю.Г., Мершин К.В., Мукаров М.А., Наконечников С.Н., Саидова М.А., Сарыбаев А.Ш., Сергиенко В.Б., Стукалова О.В., Филиппова Е.В., Чернявский А.М., Чернявский М.А., Шалаева С.В., Шмалц А.А. Евразийские рекомендации по диагностике и лечению хронической тромбоэмболической легочной гипертензии (2020). Евразийский кардиологический журнал 2021;1(34):6-43.
45. Chowdhury MA, Moukarbel GV, Gupta R, Frank SM, Anderson AM, Liu LC, Khouri SJ. Endothelin 1 is associated with heart failure hospitalization and long-term mortality in patients with heart failure with preserved ejection fraction and pulmonary hypertension. Cardiology 2019;143(3-4):124-33.
46. Watanabe T. The emerging roles of chromogranins and derived polypeptides in atherosclerosis, diabetes, and coronary heart disease. International Journal of Molecular Sciences 2021 Jun;22(11):6118.
47. Алиева А.М., Пинчук Т.В., Воронкова К.В., Шнахова Л.М., Эттингер О.А., Ахмедова М.Ф., Валиев Р.К., Калова М.Р., Гасанова Э.Т., Никитин И.Г. Неоптерин – биомаркер хронической сердечной недостаточности (обзор современной литературы). Consilium Medicum 2021;23(10):756-9.
48. Lanser L, Pölzl G, Fuchs D, Weiss G, Kurz K. Neopterin is associated with disease severity and outcome in patients with non-ischaemic heart failure. Journal of Clinical Medicine 2019 Dec;8(12):2230.
49. Baskal S, Büttner P, Werner S, Besler C, Lurz P, Thiele H, Tsikas D. Profile of urinary amino acids and their post-translational modifications (PTM) including advanced glycation end-products (AGEs) of lysine, arginine and cysteine in lean and obese ZSF1 rats. Amino Acids 2021 Jul 11. doi: 10.1007/s00726-021-03042-3. Online ahead of print.
50. Li DM, Li BX, Yang LJ, Gao P, Ma ZY, Li ZJ. Diagnostic value of circulating microRNA-208a in differentiation of preserved from reduced ejection fraction heart failure. Heart & Lung 2021 Jan-Feb;50(1):71-4.
51. Ben-Nun D, Buja LM, Fuentes F. Prevention of heart failure with preserved ejection fraction (HFpEF): reexamining microRNA-21 inhibition in the era of oligonucleotide-based therapeutics. Cardiovascular Pathology 2020 Nov-Dec;49:107243.
52. Biasucci LM, Maino A, Grimaldi MC, Cappannoli L, Aspromonte N. Novel biomarkers in heart failure: new insight in pathophysiology and clinical perspective. Journal of Clinical Medicine 2021 Jun;10(13):2771.
53. Осокина А.В., Каретникова В.Н., Поликутина О.М., Печерина Т.Б., Груздева О.В., Дылева Ю.А., Коков А.Н., Брель Н.К., Барбараш О.Л. Значение метаболического фенотипа и сывороточных проколлагенов для формирования постинфарктного кардиофиброза у пациентов с сохраненной фракцией выброса. Креативная кардиология 2021;15(2):194-206.
54. Eiros R, Romero-González G, Gavira JJ, Beloqui O, Colina I, Fortún Landecho M, López B, González A, Díez J, Ravassa S. Does chronic kidney disease facilitate malignant myocardial fibrosis in heart failure with preserved ejection fraction of hypertensive origin? Journal of Clinical Medicine 2020 Feb;9(2):404.
55. Duprez DA, Gross MD, Kizer JR, Ix JH, Hundley WG, Jacobs DR Jr. Predictive value of collagen biomarkers for heart failure with and without preserved ejection fraction: MESA (Multi-Ethnic Study of Atherosclerosis). Journal of the American Heart Association 2018 Feb;7(5):e007885.
56. Rabkin SW, Tang JKK. The utility of growth differentiation factor-15, galectin-3, and sST2 as biomarkers for the diagnosis of heart failure with preserved ejection fraction and compared to heart failure with reduced ejection fraction: a systematic review. Heart Failure Reviews 2021 Jul;26(4):799-812.

References

1. Powell-Wiley TM, Ngwa J, Kebede S, Lu D, Schulte PJ, Bhatt DL, Yancy C, Fonarow GC, Albert MA. Impact of body mass index on heart failure by race/ethnicity from the get with the guidelines-heart failure (GWTG-HF) registry. JACC. Heart Failure 2018 Mar;6(3):233-42.
2. Crespo-Leiro MG, Anker SD, Maggioni AP, Coats AJ, Filippatos G, Ruschitzka F, Ferrari R, Piepoli MF, Delgado Jimenez JF, Metra M, Fonseca C, Hradec J, Amir O, Logeart D, Dahlström U, Merkely B, Drozdz J, Goncalvesova E, Hassanein M, Chioncel O, Lainscak M, Seferovic PM, Tousoulis D, Kavoliuniene A, Fruhwald F, Fazlibegovic E, Temizhan A, Gatzov P, Erglis A, Laroche C, Mebazaa A; Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Society of Cardiology Heart Failure Long-Term registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. European Journal of Heart Failure 2016 Jun;18(6):613-25.
3. Tereshchenko SN, Galyavich AS, Uskach TM, Agheyev FT, Arutyunov GP, Begrambekova YuL, Belenkov YuN, Boytsov SA, Vasyuk YuA, Garganeyeva AA, Gendlin GE, Ghilyarevskiy SR, Glezer MG, Gauthier SV, Gupalo EM, Dovzhenko TV, Drapkina OM, Duplyakov DV, Zhirov IV, Zateyshchikov DA, Kobalava ZhD, Koziolova NA, Koroteyev AV, Libis RA, Lopatin YuM, Mareyev VYu, Mareyev YuV, Matskeplishvili ST, Nasonova SN, Narusov OYu, Nedoshivin AO, Ovchinnikov AG, Orlova YaA, Perepech NB, Samko AN, Saydova MA, Safiullina AA, Sitnikova MYu, Skvortsov AA, Skibitskiy VV, Stukalova OV, Tarlovskaya EI, Tereshchenko AS, Chesnikova AI, Fomin IV, Shevchenko AO, Shaposhnik II, Sharia MA, Shlyakhto EV, Yavelov IS, Yakushin SS. 2020 Clinical practice guidelines for chronic heart failure. Russian Journal of Cardiology 2020;25(11):311-74 (In Russian).
4. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Piepoli MF, Price S, Rosano GMC, Ruschitzka F, Skibelund AK; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal 2021 Sep;42(36):3599-726.
5. Bozkurt B, Coats AJ, Tsutsui H, Abdelhamid M, Adamopoulos S, Albert N, Anker SD, Atherton J, Böhm M, Butler J, Drazner MH, Felker GM, Filippatos G, Fonarow GC, Fiuzat M, Gomez-Mesa JE, Heidenreich P, Imamura T, Januzzi J, Jankowska EA, Khazanie P, Kinugawa K, Lam CSP, Matsue Y, Metra M, Ohtani T, Francesco Piepoli M, Ponikowski P, Rosano GMC, Sakata Y, Seferović P, Starling RC, Teerlink JR, Vardeny O, Yamamoto K, Yancy C, Zhang J, Zieroth S. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. Journal of Cardiac Failure 2021 Apr;27(4):387-413.
6. Levinson RT, Vaitinidin NS, Farber-Eger E, Roden DM, Lasko TA, Wells QS, Mosley JD. Heart failure clinical care analysis uncovers risk reduction opportunities for preserved ejection fraction subtype. Scientific Reports 2021 Sep;11(1):18618.
7. Cho DH, Yoo BS. Current prevalence, incidence, and outcomes of heart failure with preserved ejection fraction. Heart Failure Clinics 2021 Jul;17(3):315-26.
8. van Riet EE, Hoes AW, Wagenaar KP, Limburg A, Landman MA, Rutten FH. Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review. European Journal of Heart Failure 2016 Mar;18(3):242-52.
9. Fomin IV. Chronic heart failure in Russian Federation: what do we know and what to do. Russian Journal of Cardiology 2016;21(8):7-13 (In Russian).
10. Oshchepkova EV, Lazarev NV, Satlykova DF, Tereshchenko SN. The first results of the Russian register of chronic heart failure. Kardiologiia 2015;55(5):22-8 (In Russian).
11. Brouwers FP, de Boer RA, van der Harst P, Voors AA, Gansevoort RT, Bakker SJ, Hillege HL, van Veldhuisen DJ, van Gilst WH. Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. European Heart Journal 2013 May;34(19):1424-31.
12. Silverman MG, Patel B, Blankstein R, Lima JA, Blumenthal RS, Nasir K, Blaha MJ. Impact of race, ethnicity, and multimodality biomarkers on the incidence of new-onset heart failure with preserved ejection fraction (from the multi-ethnic study of atherosclerosis). The American Journal of Cardiology 2016 May;117(9):1474-81.
13. Ho JE, Lyass A, Lee DS, Vasan RS, Kannel WB, Larson MG, Levy D. Predictors of new-onset heart failure: differences in preserved versus reduced ejection fraction. Circulation. Heart Failure 2013 Mar;6(2):279-86.
14. Gerber Y, Weston SA, Redfield MM, Chamberlain AM, Manemann SM, Jiang R, Killian JM, Roger VL. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA. Internal Medicine 2015 Jun;175(6):996-1004.
15. Tsao CW, Lyass A, Enserro D, Larson MG, Ho JE, Kizer JR, Gottdiener JS, Psaty BM, Vasan RS. Temporal trends in the incidence of and mortality associated with heart failure with preserved and reduced ejection fraction. JACC. Heart Failure 2018 Aug;6(8):678-85.
16. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. The Lancet 2003 Sep;362(9386):777-81.
17. Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, van Veldhuisen DJ, Zannad F, Zile MR, Desai AS, Claggett B, Jhund PS, Boytsov SA, Comin-Colet J, Cleland J, Düngen HD, Goncalvesova E, Katova T, Kerr Saraiva JF, Lelonek M, Merkely B, Senni M, Shah SJ, Zhou J, Rizkala AR, Gong J, Shi VC, Lefkowitz MP; PARAGON-HF Investigators and Committees. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. The New England Journal of Medicine 2019 Oct;381(17):1609-20.
18. Drapkina OM, Boytsov SA, Omelyanovskiy VV, Kontsevaya AV, Lukyanov MM, Ignatyeva VI, Derkach EV. Socio-economic impact of heart failure in Russia. Russian Journal of Cardiology 2021;26(6):81-9 (In Russian).
19. Di Palo KE, Barone NJ. Hypertension and heart failure: prevention, targets, and treatment. Heart Failure Clinics 2020 Jan;16(1):99-106.
20. Hicklin HE, Gilbert ON, Ye F, Brooks JE, Upadhya B. Hypertension as a road to treatment of heart failure with preserved ejection fraction. Current Hypertension Reports 2020 Sep;22(10):82.
21. Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiade M, Greenberg BH, O’Connor CM, Sun JL, Yancy CW, Young JB; OPTIMIZE-HF Investigators and Hospitals. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. Journal of the American College of Cardiology 2007 Aug;50(8):768-77.
22. Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction. Nature Reviews. Cardiology 2017 Oct;14(10):591-602.
23. Mareyev VY, Fomin IV, Agheyev FT, Begrambekova YL, Vasyuk YA, Garganeyeva AA, Gendlin GE, Glezer MG, Gotye SV, Dovzhenko TV, Kobalava ZD, Koziolova NA, Koroteyev AV, Mareyev YV, Ovchinnikov AG, Perepech NB, Tarlovskaya EI, Chesnikova AI, Shevchenko AO, Arutyunov GP, Belenkov YuN, Galyavich AS, Gilyarevskiy SR, Drapkina OM, Duplyakov DV, Lopatin YuM, Sitnikova MYu, Skibitskiy VV, Shlyakhto EV. Russian Heart Failure Society; Russian Society of Cardiology. Russian Scientific Medical Society of Internal Medicine Guidelines for heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, prevention and treatment. Kardiologiia 2018;58(6S):8-158 (In Russian).
24. Vasyuk YuA, Shupenina EYu, Namazova GA, Dubrovskaya TI. Novel algorithms for diagnosing heart failure with preserved ejection fraction in patients with hypertension and obesity. Cardiovascular Therapy and Prevention 2021;20(1):65-70 (In Russian).
25. Pieske B, Tschöpe C, de Boer RA, Fraser AG, Anker SD, Donal E, Edelmann F, Fu M, Guazzi M, Lam CSP, Lancellotti P, Melenovsky V, Morris DA, Nagel E, Pieske-Kraigher E, Ponikowski P, Solomon SD, Vasan RS, Rutten FH, Voors AA, Ruschitzka F, Paulus WJ, Seferovic P, Filippatos G. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Heart Journal 2019 Oct;40(40):3297-317.
26. Reddy YNV, Carter RE, Obokata M, Redfield MM, Borlaug BA. A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. Circulation 2018 Aug;138(9):861-70.
27. Larina VN, Lunev VI. The value of biomarkers in the diagnosis and prognosis of heart failure in older age. The Russian Archives of Internal Medicine 2021;11(2):98-110 (In Russian).
28. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P; Authors/Task Force Members; Document Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Journal of Heart Failure 2016 Aug;18(8):891-975.
29. Salzano A, D’Assante R, Israr MZ, Eltayeb M, D’Agostino A, Bernieh D, De Luca M, Rega S, Ranieri B, Mauro C, Bossone E, Squire IB, Suzuki T, Marra AM. Biomarkers in heart failure: clinical insights. Heart Failure Clinics 2021 Apr;17(2):223-43.
30. Seferović PM, Jankowska E, Coats AJS, Maggioni AP, Lopatin Y, Milinković I, Polovina M, Lainščak M, Timmis A, Huculeci R, Vardas P; Task Force of the HFA Atlas, and the ESC Atlas of Cardiology leadership, developed in collaboration with the National Heart Failure Societies of the ESC member and ESC affiliated member countries. The Heart Failure Association Atlas: rationale, objectives, and methods. European Journal of Heart Failure 2020 Apr;22(4):638-45.
31. Dokainish H, Teo K, Zhu J, Roy A, AlHabib KF, ElSayed A, Palileo-Villaneuva L, Lopez-Jaramillo P, Karaye K, Yusoff K, Orlandini A, Sliwa K, Mondo C, Lanas F, Prabhakaran D, Badr A, Elmaghawry M, Damasceno A, Tibazarwa K, Belley-Cote E, Balasubramanian K, Islam S, Yacoub MH, Huffman MD, Harkness K, Grinvalds A, McKelvie R, Bangdiwala SI, Yusuf S; INTER-CHF Investigators. Global mortality variations in patients with heart failure: results from the International Congestive Heart Failure (INTER-CHF) prospective cohort study. The Lancet. Global Health 2017 Jul;5(7):e665-72.
32. Hessel FP. Overview of the socio-economic consequences of heart failure. Cardiovascular Diagnosis and Therapy 2021 Feb;11(1):254-62.
33. Ibrahim NE, Burnett JC Jr, Butler J, Camacho A, Felker GM, Fiuzat M, O’Connor C, Solomon SD, Vaduganathan M, Zile MR, Januzzi JL Jr. Natriuretic peptides as inclusion criteria in clinical trials: a JACC: Heart Failure Position Paper. JACC: Heart Failure 2020 May;8(5):347-58.
34. Berezin AE, Berezin AA. Biomarker-based guideline-directed medical therapy of heart failure: the gap between guidelines and clinical practice. EMJ Cardiology 2021 Oct;9(1):51-60.
35. Song Y, Li F, Xu Y, Liu Y, Wang Y, Han X, Fan Y, Cao J, Luo J, Sun A, Hu K, Zhou J, Ge J. Prognostic value of sST2 in patients with heart failure with reduced, mid-range and preserved ejection fraction. International Journal of Cardiology 2020 Apr;304:95-100.
36. Watson CJ, Gallagher J, Wilkinson M, Russell-Hallinan A, Tea I, James S, O’Reilly J, O’Connell E, Zhou S, Ledwidge M, McDonald K. Biomarker profiling for risk of future heart failure (HFpEF) development. Journal of Translational Medicine 2021 Feb;19(1):61.
37. Castiglione V, Aimo A, Vergaro G, Saccaro L, Passino C, Emdin M. Biomarkers for the diagnosis and management of heart failure. Heart Failure Reviews 2021 Apr 14. doi: 10.1007/s10741-021-10105-w. Online ahead of print.
38. Yamamoto M, Seo Y, Ishizua T, Nakagawa D, Sato K, Machino-Ohtsuka T, Nishi I, Hamada-Harimura Y, Sai S, Sugano A, Baba M, Higuchi H, Aonuma K, Ohte N, Ieda M. Comparison of soluble ST2, pentraxin-3, galectin-3, and high-sensitivity troponin T of cardiovascular outcomes in patients with acute decompensated heart failure. Journal of Cardiac Failure 2021 Nov;27(11):1240-50.
39. Trippel TD, Mende M, Düngen HD, Hashemi D, Petutschnigg J, Nolte K, Herrmann-Lingen C, Binder L, Hasenfuss G, Pieske B, Wachter R, Edelmann F. The diagnostic and prognostic value of galectin-3 in patients at risk for heart failure with preserved ejection fraction: results from the DIAST-CHF study. ESC Heart Failure 2021 Apr;8(2):829-41.
40. Badrov MB, Mak S, Floras JS. Cardiovascular autonomic disturbances in heart failure with preserved ejection fraction. The Canadian Journal of Cardiology 2021 Apr;37(4):609-20.
41. Vergaro G, Aimo A, Prontera C, Ghionzoli N, Arzilli C, Zyw L, Taddei C, Gabutti A, Poletti R, Giannoni A, Mammini C, Spini V, Passino C, Emdin M. Sympathetic and renin-angiotensin-aldosterone system activation in heart failure with preserved, mid-range and reduced ejection fraction. International Journal of Cardiology 2019 Dec;296:91-7.
42. Jimenez-Marrero S, Moliner P, Rodríguez-Costoya I, Enjuanes C, Alcoberro L, Yun S, Gonzalez-Costello J, Garay A, Tajes M, Calero E, Hidalgo E, Guerrero C, García-Romero E, Díez-López C, Cainzos-Achirica M, Comin-Colet J. Sympathetic activation and outcomes in chronic heart failure: does the neurohormonal hypothesis apply to mid-range and preserved ejection fraction patients? European Journal of Internal Medicine 2020 Nov;81:60-6.
43. Borovac JA, D’Amario D, Bozic J, Glavas D. Sympathetic nervous system activation and heart failure: current state of evidence and the pathophysiology in the light of novel biomarkers. World Journal of Cardiology 2020 Aug;12(8):373-408.
44. Chazova IE, Martynyuk TV, Valiyeva ZS, Azizov VA, Akchurin RS, Ansheles AA, Vasiltseva OYa, Veselova TN, Galyavich AS, Gorbachevskiy SV, Danilov NM, Yedemskiy AG, Zelveyan PA, Lazareva IV, Matchin YuG, Mershin KV, Mukarov MA, Nakonechnikov SN, Saidova MA, Sarybaev AS, Sergienko VB, Stukalova OV, Filippov EV, Chernyavskiy AM, Chernyavskiy MA, Shalayev SV, Shmalts AA. Eurasian Association of Cardiology (EAC) guidelines for the diagnosis and treatment of chronic thromboembolic pulmonary hypertension (2020). Eurasian Heart Journal 2021;1(34):6-43 (In Russian).
45. Chowdhury MA, Moukarbel GV, Gupta R, Frank SM, Anderson AM, Liu LC, Khouri SJ. Endothelin 1 is associated with heart failure hospitalization and long-term mortality in patients with heart failure with preserved ejection fraction and pulmonary hypertension. Cardiology 2019;143(3-4):124-33.
46. Watanabe T. The emerging roles of chromogranins and derived polypeptides in atherosclerosis, diabetes, and coronary heart disease. International Journal of Molecular Sciences 2021 Jun;22(11):6118.
47. Aliyeva AM, Pinchuk TV, Voronkova KV, Shnakhova LM, Ettinger OA, Akhmedova MF, Valiyev RK, Kalova MR, Gasanova ET, Nikitin IG. Neopterin is a biomarker of chronic heart failure: review of modern literature. Consilium Medicum 2021;23(10):756-9 (In Russian).
48. Lanser L, Pölzl G, Fuchs D, Weiss G, Kurz K. Neopterin is associated with disease severity and outcome in patients with non-ischaemic heart failure. Journal of Clinical Medicine 2019 Dec;8(12):2230.
49. Baskal S, Büttner P, Werner S, Besler C, Lurz P, Thiele H, Tsikas D. Profile of urinary amino acids and their post-translational modifications (PTM) including advanced glycation end-products (AGEs) of lysine, arginine and cysteine in lean and obese ZSF1 rats. Amino Acids 2021 Jul 11. doi: 10.1007/s00726-021-03042-3. Online ahead of print.
50. Li DM, Li BX, Yang LJ, Gao P, Ma ZY, Li ZJ. Diagnostic value of circulating microRNA-208a in differentiation of preserved from reduced ejection fraction heart failure. Heart & Lung 2021 Jan-Feb;50(1):71-4.
51. Ben-Nun D, Buja LM, Fuentes F. Prevention of heart failure with preserved ejection fraction (HFpEF): reexamining microRNA-21 inhibition in the era of oligonucleotide-based therapeutics. Cardiovascular Pathology 2020 Nov-Dec;49:107243.
52. Biasucci LM, Maino A, Grimaldi MC, Cappannoli L, Aspromonte N. Novel biomarkers in heart failure: new insight in pathophysiology and clinical perspective. Journal of Clinical Medicine 2021 Jun;10(13):2771.
53. Osokina AV, Karetnikova VN, Polikutina OM, Pecherina TB, Gruzdeva OV, Dyleva YuA, Kokov AN, Brel’ NK, Barbarash OL. Significance of the metabolic phenotype and serum procollagens for the formation of postinfarction myocardial fibrosis in patients with preserved ejection fraction. Creative Cardiology 2021;15(2):194-206 (In Russian).
54. Eiros R, Romero-González G, Gavira JJ, Beloqui O, Colina I, Fortún Landecho M, López B, González A, Díez J, Ravassa S. Does chronic kidney disease facilitate malignant myocardial fibrosis in heart failure with preserved ejection fraction of hypertensive origin? Journal of Clinical Medicine 2020 Feb;9(2):404.
55. Duprez DA, Gross MD, Kizer JR, Ix JH, Hundley WG, Jacobs DR Jr. Predictive value of collagen biomarkers for heart failure with and without preserved ejection fraction: MESA (Multi-Ethnic Study of Atherosclerosis). Journal of the American Heart Association 2018 Feb;7(5):e007885.
56. Rabkin SW, Tang JKK. The utility of growth differentiation factor-15, galectin-3, and sST2 as biomarkers for the diagnosis of heart failure with preserved ejection fraction and compared to heart failure with reduced ejection fraction: a systematic review. Heart Failure Reviews 2021 Jul;26(4):799-812.
  

[ Содержание выпуска N 4 | Выпуски журнала | Список журналов ]